To further verify whether CD8+ T cells are responsible for the enhancement of anti-tumor efficacy of α-PD-L1 plus IFNα-MSCs, we depleted CD8+ T cells by intraperitoneal injection α-CD8 antibody (clone number 2.43). The gene discussed is CD8A; the disease is neoplasm.